Clinical Trial Update: Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies [Phase 2]

View source ↗

Summary

An extension study assessing long-term safety and efficacy of Myozyme (alglucosidase alfa) in Pompe disease patients who were previously enrolled in Genzyme-spo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii
• Pompe Disease

Drugs mentioned

• Myozyme (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Pompe Disease Infantile-Onset, Glycogen Storage Disease Type II | Phase 2 | Status: COMPLETED